Get the Stockscreener App
429.60
1.20%
-5.22
Pre-market:
429.10
-0.50
-0.12%
Vertex Pharmaceuticals Inc stock is traded at $429.60, with a volume of 2.94M.
It is down -1.20% in the last 24 hours and down -9.05% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$434.82
Open:
$430.165
24h Volume:
2.94M
Relative Volume:
1.85
Market Cap:
$128.25B
Revenue:
$11.10B
Net Income/Loss:
$-988.90M
P/E Ratio:
-109.59
EPS:
-3.92
Net Cash Flow:
$-1.26B
1W Performance:
-13.88%
1M Performance:
-9.05%
6M Performance:
-16.86%
1Y Performance:
+2.57%
1-Day Range:
$423.40
$432.13
1-Week Range:
$423.40
$509.00
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
4 No-Brainer Stocks to Buy Right Now - The Motley Fool
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq
Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN
Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha
Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - TradingView
Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus
Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - MSN
Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus
Vertex stock rating downgraded at Wolfe Research By Investing.com - Investing.com UK
Vertex On Track To Significantly Improve Revenue And Earnings By 2030 (NASDAQ:VRTX) - Seeking Alpha
Leerink Partners Downgrades Vertex Pharmaceuticals (LSE:0QZU) - Nasdaq
Vertex Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches - insights.citeline.com
Vertex Pharmaceuticals (VRTX) Analyst Rating Update | VRTX Stock News - GuruFocus
Goldman Sachs Raises Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus
Big-Name Biotech Dives 10% On A Series Of Setbacks - Investor's Business Daily
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Yahoo Finance
Jim Cramer on Vertex (VRTX): “Vertex’s Painkiller Could Be Revolutionary” - Insider Monkey
Tuesday Sector Laggards: Healthcare, Industrial - Nasdaq
Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia - Fierce Pharma
Vertex to manufacture gene therapies in New Hampshire - The Business Journals
Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment Charge - Yahoo Finance
Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Price Target Raised by Morgan Stanley | VRTX Stock News - GuruFocus
Why Vertex Pharmaceuticals Stock Is Down Sharply - Barron's
Vertex Pharmaceuticals (VRTX) Stock Drops 12% Amid Rising Costs and IP Issues - GuruFocus
Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened - TradingView
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More - Investopedia
Cantor Fitzgerald maintains Vertex stock Overweight with $535 target By Investing.com - Investing.com UK
Bernstein raises Vertex stock target to $462 on market resilience By Investing.com - Investing.com UK
Stock Movers: Palantir, Vertex Pharmaceuticals, DoorDash - Bloomberg
Stifel holds Vertex stock with $194 target post-Q1 results - Investing.com
Why Vertex Pharmaceuticals Stock Is Sinking Today - MSN
Vertex Pharmaceuticals (VRTX) Stock Declines After Earnings Miss - GuruFocus
Vertex Pharmaceuticals Stock Sinks as Costs Soar - Investopedia
2 Pharma Stocks Staging Big Post-Earnings Moves - Schaeffer's Investment Research
Vertex Pharmaceuticals (VRTX) Price Target Raised by JP Morgan | VRTX Stock News - GuruFocus
Despite Q1 miss, pain drug launch and new CF therapy drive Vertex growth - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rat - GuruFocus
Vertex Pharmaceuticals (VRTX) Target Price Lowered by Scotiabank Analyst | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rating from Cantor Fitzgerald | VRTX Stock News - GuruFocus
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617 - marketscreener.com
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):